

PATIENT DEMOGRAPHICS:	
PATIENT NAME:	PREFERRED CONTACT #:
DATE OF REFERRAL:	SECONDARY CONTACT #:
SOCIAL SECURITY NUMBER:	ADDRESS:
DATE OF BIRTH:	CITY, STATE, ZIP:

PRIMARY DIAGNOSIS: PLEASE PROVIDE ICD-IO CODE:	
<input type="checkbox"/> L20.____ - Atopic Dermatitis	<input type="checkbox"/> L40.4 - Guttate psoriasis
<input type="checkbox"/> L40.0 - Psoriasis vulgaris	<input type="checkbox"/> L40.8 - Other psoriasis
<input type="checkbox"/> L40.1 - Generalized pustular psoriasis	<input type="checkbox"/> L40.9 - Psoriasis, unspecified
<input type="checkbox"/> L40.2 Acrodermatitis continua	<input type="checkbox"/> L73.2 - Hidradentis suppurativa
<input type="checkbox"/> L40.3 - Pustulosis palmaris et plantaris	<input type="checkbox"/> Other: _____ - _____

PRIOR THERAPY: PLEASE PROVIDE MEDICATION HISTORY	
PRIOR THERAPY (if any):	APPROX START DATE: _____
<input type="checkbox"/> TOPICALS: _____	APPROX END DATE: _____
<input type="checkbox"/> PUVA	REASON FOR DISCONTINUATION:
<input type="checkbox"/> UVB	_____
<input type="checkbox"/> METHOTREXATE	_____
<input type="checkbox"/> CYCLOSPORINE	_____
<input type="checkbox"/> ORAL RETINOIDS	_____
<input type="checkbox"/> _____	_____

PATIENT INFORMATION:	
ALLERGIES: <input type="checkbox"/> NKDA	FIRST DOSE: <input type="checkbox"/> Y <input type="checkbox"/> N
	DATE OF LAST INFUSION: _____
	NEXT DOSE DUE BY: _____
HEIGHT: ____ Ft ____ In WEIGHT: ____ Lb or ____ Kg	ACCESS/LINE TYPE: <input type="checkbox"/> PIV <input type="checkbox"/> PORT <input type="checkbox"/> PICC <input type="checkbox"/> MIDLINE
GENDER: <input type="checkbox"/> F <input type="checkbox"/> M	OTHER: _____

REQUIRED DOCUMENTATION: Please provide a copy of the following documents.

1. INSURANCE CARD (Front & Back) 2. PATIENT DEMOGRAPHICS 3. MOST RECENT LABS 4. H & P 5. LABS

MEDICATION WASTE: FOR REMICADE	PRN & PREMEDICATIONS:		
Authorized to round up to nearest vial size? <input type="checkbox"/> YES <input type="checkbox"/> NO	MEDICATIONS	30 minutes prior every infusion	PRN
TESTING RESULTS: If prescribing: Cimzia, Humira, Remicade, Skyrizi, Stelara	Acetaminophen ____ mg PO	<input type="checkbox"/>	<input type="checkbox"/> PRN every ____ hours for mild or moderate infusion reaction.
	Diphenhydramine ____ mg PO	<input type="checkbox"/>	<input type="checkbox"/> PRN every ____ hours for mild or moderate infusion reaction.
TB SCREENING DATE: _____	Diphenhydramine ____ mg diluted in 10mL 0.9% NaCl slow IV push over 2-3 minutes.	<input type="checkbox"/>	<input type="checkbox"/> PRN every ____ hours for mild or moderate infusion reaction.
HEPATITIS-B PANEL DATE: _____	Methylprednisolone ____ mg IV push over 5 minutes.	<input type="checkbox"/>	
ADVERSE REACTION & ANAPHYLAXIS ORDERS:	Methylprednisolone 100mg IV	<input type="checkbox"/>	
<input type="checkbox"/> ADMINISTER ACUTE INFUSION AND ANAPHYLAXIS MEDICATIONS PER GREENHILL INFUSION POLICY AND PROCEDURE (See Reverse Side)			
<input type="checkbox"/> OTHER: (please fax other reaction orders if checking this box)			

MEDICATION SELECTION:

 CIMZIA <small>(certolizumab pegol)</small>	INDUCTION DOSE: <input type="checkbox"/> 400 MG SC WEEKS 0, 2, & 4 MAINTENANCE DOSE: <input type="checkbox"/> 400 MG SC EVERY 2 WEEKS REFILLS: _____
 Cosentyx [®] <small>(secukinumab)</small>	INDUCTION DOSE: <input type="checkbox"/> 150 MG SC WEEKS 0, 1, 2, 3, & 4 or <input type="checkbox"/> 300 MG SC WEEKS 0, 1, 2, 3, & 4 MAINTENANCE DOSE: <input type="checkbox"/> 300 MG SC EVERY 4 WEEKS REFILLS: _____
DUPIXENT [™] <small>(dupilumab)</small> 	INDUCTION DOSE: <input type="checkbox"/> 400 MG SC or <input type="checkbox"/> 600 MG SC MAINTENANCE DOSE: <input type="checkbox"/> 200 MG SC EVERY OTHER WEEK or <input type="checkbox"/> 300 MG SC QOW REFILLS: _____
HUMIRA <small>adalimumab</small>	INDUCTION DOSE: <input type="checkbox"/> 160 MG SC THEN 80 MG SC ON DAY 15, THEN 40 MG ON DAY 29 <input type="checkbox"/> 80 MG SC THEN 40 MG SC ON DAY 8, THEN 40 MG EVERY 2 WEEKS MAINTENANCE DOSE: <input type="checkbox"/> 40 MG SC EVERY TWO WEEKS <input type="checkbox"/> 40 MG SC EVERY WEEK REFILLS: _____
 ILUMYA [™] <small>tildrakizumab-asmn</small>	INDUCTION DOSE: <input type="checkbox"/> 100 MG SC WEEKS 0 & 4 MAINTENANCE DOSE: <input type="checkbox"/> 100 MG SC EVERY 12 WEEKS REFILLS: _____
 Remicade [®] <small>INFLIXIMAB</small>	INDUCTION DOSE: <input type="checkbox"/> 5 MG/KG IV WEEKS 0, 2, & 6 MAINTENANCE DOSE: <input type="checkbox"/> 5 MG/KG or <input type="checkbox"/> 10 MG/KG IV EVERY 8 WEEKS ALTERNATIVE: _____ MG/KG IV EVERY _____ WEEKS REFILLS: _____
 Skyrizi [™] <small>risankizumab-rzaa</small>	INDUCTION DOSE: <input type="checkbox"/> 150 MG SC WEEKS 0 & 4 MAINTENANCE DOSE: <input type="checkbox"/> 150 MG SC EVERY 12 WEEKS REFILLS: _____
 Stelara [®] <small>(ustekinumab)</small>	INDUCTION DOSE: <input type="checkbox"/> 45 MG SC THEN 45 MG SC 4 WEEKS LATER <input type="checkbox"/> 90 MG SC THEN 90 MG SC 4 WEEKS LATER MAINTENANCE DOSE: <input type="checkbox"/> 45 MG SC EVERY 12 WEEKS AFTER LOADING DOSE <input type="checkbox"/> 90 MG SC EVERY 90 WEEKS AFTER LOADING DOSE REFILLS: _____
taltz [®] <small>(ixekizumab) injection</small>	INDUCTION DOSE: <input type="checkbox"/> 160 MG AT WEEKS 0, FOLLOWED BY 80 MG AT WEEKS 2, 4, 6, 8, 10, & 12 MAINTENANCE DOSE: <input type="checkbox"/> 80 MG SC EVERY 4 WEEKS REFILLS: _____
 Tremfya [®] <small>(guselkumab)</small>	INDUCTION DOSE: <input type="checkbox"/> 100 MG SC AT WEEKS 0 & 4 MAINTENANCE DOSE: <input type="checkbox"/> 100 MG SC EVERY 8 WEEKS REFILLS: _____

PRESCRIBER INFORMATION:

PHYSICIAN NAME: _____	PHONE: _____
OFFICE CONTACT: _____	FAX: _____
ADDRESS: _____	LICENSE #: _____
CITY, STATE, ZIP: _____	NPI: _____
PHYSICIAN SIGNATURE: _____	DATE: _____